The DOI matches its Crossref record; 774 of the 774 references it cites were found in a registry or an index.
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Abstract
A number of therapeutic drugs with different structures and mechanisms of action have been reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes. The bioactivation gives rise to reactive metabolites/intermediates, which readily confer covalent binding to various target proteins by nucleophilic substitution and/or Schiff's base mechanism. These drugs include analgesics (e.g., acetaminophen), antibacterial agents (e.g., sulfonamides and macrolide antibiotics), anticancer drugs (e.g., irinotecan), antiepileptic drugs (e.g., carbamazepine), anti-HIV agents (e.g., ritonavir), antipsychotics (e.g., clozapine), cardiovascular drugs (e.g., procainamide and hydralazine), immunosupressants (e.g., cyclosporine A), inhalational anesthetics (e.g., halothane), nonsteroidal anti-inflammatory drugs (NSAIDSs) (e.g., diclofenac), and steroids and their receptor modulators (e.g., estrogens and tamoxifen). Some herbal and dietary constituents are also bioactivated to reactive metabolites capable of binding covalently and inactivating cytochrome P450s (CYPs). A number of important target proteins of drugs have been identified by mass spectrometric techniques and proteomic approaches. The covalent binding and formation of drug-protein adducts are generally considered to be related to drug toxicity, and selective protein covalent binding by drug metabolites may lead to selective organ toxicity. However, the mechanisms involved in the protein adduct-induced toxicity are largely undefined, although it has been suggested that drug-protein adducts may cause toxicity either through impairing physiological functions of the modified proteins or through immune-mediated mechanisms. In addition, mechanism-based inhibition of CYPs may result in toxic drug-drug interactions. The clinical consequences of drug bioactivation and covalent binding to proteins are unpredictable, depending on many factors that are associated with the administered drugs and patients. Further studies using proteomic and genomic approaches with high throughput capacity are needed to identify the protein targets of reactive drug metabolites, and to elucidate the structure-activity relationships of drug's covalent binding to proteins and their clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–774 of 774
A Comparison of the Physicochemical and Biological Properties of Mirtazapine and Mianserin
Kelder, J., Funke, C. W., de Boer, T., Delbressine, L. P. C., Leysen, D. C., & Nickolson, V. J. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06814.x · Cited by 54
Steady‐State Pharmacokinetics and Dose Proportionality of Troglitazone and Its Metabolites
Loi, C., Alvey, C. W., Vassos, A. B., Randinitis, E. J., Sedman, A. J., & Koup, J. R. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008533 · Cited by 54
Pan, L. P., Wijnant, P., Vriendt, C. D., Rosseel, M. T., & Belpaire, F. M. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.t01-1-00629.x · Cited by 54
von Schmiedeberg, S., Fritsche, E., Rönnau, A. C., Specker, C., Golka, K., Richter-Hintz, D., Schuppe, H. ‐., Lehmann, P., Ruzicka, T., Esser, C., et al. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4857-7_21 · Cited by 54
PROTEIN-REACTIVE METABOLITES OF CARBAMAZEPINE IN MOUSE LIVER MICROSOMES
Lillibridge, J. H., Amore, B. M., Slattery, J. T., Kalhorn, T. F., Nelson, S. D., Finnell, R. H., & Bennett, G. D. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)09173-1 · Cited by 54
Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione.
Pessayre, D., Tinel, M., Larrey, D. G., Cobert, B., Funck‐Brentano, C., & Babany, G. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33535-4 · Cited by 53
Störmer, E., Moltke, L. L., & Greenblatt, D. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38970-0 · Cited by 53
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Anderson, J. J. (1994) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199403000-00024 · Cited by 53
Dhillon, S., Oxley, J. R., & Richens, A. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01397.x · Cited by 53
Glucuronidation of Acetaminophen Catalyzed by Multiple Rat Phenol UDP-Glucuronosyltransferases
Kessler, F. K., Kessler, M. R., Auyeung, D. J., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.324 · Cited by 53
The role of mitochondrial injury in bromobenzene and furosemide induced hepatotoxicity
Wong, S. G. W., Card, J. W., & Racz, W. J. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(00)00218-6 · Cited by 53
The High Incidence of Valproate Hepatotoxicity in Infants May Relate to Familial Metabolic Defects
APPLETON, R. E., Farrell, K., Applegarth, D. A., Dimmick, J. E., Wong, L., & Davidson, A. G. F. (1990) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100030353 · Cited by 53
Hyeseon, M., Shane, B., & Stokstad, E. L. R. (1988) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(88)90097-9 · Cited by 52
Adverse Reactions with ??-Adrenoceptor Blocking Drugs An Update
Lewis, R. V., & Lofthouse, C. (1993) · Drug Safety · doi:10.2165/00002018-199309040-00005 · Cited by 52
Brown, H. R., Benavides, G., Giridhar, J., Tyler, R. D., 倪, 红., Yoon, L., Gardner, G. H., Hyder, K., & Morgan, K. T. (2002) · Toxicologic Pathology · doi:10.1080/01926230213169 · Cited by 52
Clinically significant pharmacokinetic drug interactions with benzodiazepines
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00247.x · Cited by 52
Separation and detection methods for covalent drug–protein adducts
Zhou, S. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(03)00399-4 · Cited by 52
Self-citationVoorman, R. L., Maio, S. M., Hauer, M. J., Sanders, P. E., Payne, N. A., & Ackland, M. J. (1998) · PubMed · Cited by 52
Target Proteins in Human Autoimmunity: Cytochromes P450 and Udp-Glycoronosyltransferases
Obermayer–Straub, P., Strassburg, C. P., & Manns, M. P. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/910107 · Cited by 52
Biochemical and Molecular Teratology of Fetal Hydantoin Syndrome
Buehler, B. A., Rao, V. H., & Finnell, R. H. (1994) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30074-4 · Cited by 52
Barzilai, A., Zilkha‐Falb, R., Daily, D., Stern, N., Offen, D., Ziv, I., Melamed, E., & Shirvan, A. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_4 · Cited by 51
Dapsone: unapproved uses or indications
Wolf, R., Tüzün, B., & Tüzün, Y. (2000) · Clinics in Dermatology · doi:10.1016/s0738-081x(99)00093-0 · Cited by 51
Prostaglandin H Synthases and their Importance in Chemical Toxicity
Vogel, C. F. A. (2000) · Current Drug Metabolism · doi:10.2174/1389200003338884 · Cited by 50
Valproic acid and plasma levels of phenobarbital
Bruni, J., Wilder, B. J., Perchalski, R. J., et al. (1980) · Neurology · doi:10.1212/wnl.30.1.94 · Cited by 50
Ju, C. H., & Uetrecht, J. (1998) · PubMed · Cited by 50
5´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis
Price, D. K., Ando, Y., Kruger, E. A., Weiß, M., & Figg, W. D. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200202000-00017 · Cited by 50
Karanam, B. V., Vincent, S. H., Newton, D. J., Wang, R. W., & Chiu, S. H. L. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07572-5 · Cited by 50
Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins
Pantarotto, C., Arboix, M., Sezzano, P., & Abbruzzi, R. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90372-0 · Cited by 49
Olsen, J., Bjørnsdottir, I., Tjørnelund, J., & Hansen, S. H. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00026-2 · Cited by 48
Hydroxylated Metabolites of Thalidomide: Formation In-vitro and In-vivo in Man
Eriksson, T., Björkman, S. E., Roth, B., Björk, H., & Höglund, P. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb03368.x · Cited by 48
Combination analgesic-induced kidney disease: The australian experience
Duggin, G. G. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90568-5 · Cited by 48
Arlen, R. R., & Wells, P. G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13119-4 · Cited by 48
Pharmacological studies on the potentiation of phenytoin teratogenicity by acetaminophen
Lum, J. T., & Wells, P. G. (1986) · Teratology · doi:10.1002/tera.1420330109 · Cited by 47
Monitoring 2‐D gel‐induced modifications of proteins by MALDI‐TOF mass spectrometry
Hamdan, M. H., Galvani, M., & Righetti, P. G. (2001) · Mass Spectrometry Reviews · doi:10.1002/mas.10000 · Cited by 47
Acute hepatitis associated with herb (Teucrium capitatum L.) administration
Dourakis, S. P., Papanikolaou, I. S., Tzemanakis, E. N., & Hadziyannis, S. J. (2002) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200206000-00016 · Cited by 47
Teratogenicity of carbamazepine in rats
Vorhees, C. V., Acuff‐Smith, K. D., Weisenburger, W. P., & Minck, D. R. (1990) · Teratology · doi:10.1002/tera.1420410308 · Cited by 47
Bioactivation of Tamoxifen by Recombinant Human Cytochrome P450 Enzymes
Notley, L. M., de Wolf, C. J. F., Wunsch, R. M., Lancaster, R. G., & Gillam, E. M. J. (2002) · Chemical Research in Toxicology · doi:10.1021/tx0100439 · Cited by 47
Hepatotoxizität von Arzneimitteln pflanzlichen Ursprungs
Stickel, F., Seitz, H. K., Hahn, E. G., & Schuppan, D. (2001) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2001-11772 · Cited by 47
Human halothane metabolism, lipid peroxidation, and cytochromes P 450 2A6 and P 450 3A4
Kharasch, E. D., Hankins, D. C., Fenstamaker, K., & Cox, K. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050707 · Cited by 47
Studies on the reactivity of acyl glucuronides—IV
King, A. R., & DICKINSON, R. G. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90248-u · Cited by 46
Nappi, A. J., & Vass, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009872200 · Cited by 46
Immunopharmacology of hypersensitivity reactions to drugs
Naisbitt, D. J., Pirmohamed, M., & Park, B. K. (2003) · Current Allergy and Asthma Reports · doi:10.1007/s11882-003-0006-9 · Cited by 46
Masubuchi, Y., & Horie, T. (1999) · Chemical Research in Toxicology · doi:10.1021/tx9901276 · Cited by 46
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly*
Jorga, K. M., S\[ecedil]dek, G., Fotteler, B., Zürcher, G., Nielsen, T., & AITKEN, J. W. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90033-3 · Cited by 46
Cyclosporine-Amiodarone Interaction
Chitwood, K. K., Abdul-Haqq, A. J., & HEIM-DUTHOY, K. L. (1993) · Annals of Pharmacotherapy · doi:10.1177/106002809302700506 · Cited by 46
N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system.
Uetrecht, J., Shear, N. H., & ZAHID, N. D. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08169-3 · Cited by 46
Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds
Mansuy, D. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80493-x · Cited by 45
Kuhn, D. M., & Arthur, R. E. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00238-7 · Cited by 45
McHugh, S., & Rowland, T. L. (1997) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1997.tb08310.x · Cited by 45
Slott, V. L., & Hales, B. F. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90503-x · Cited by 45
van der Ven, A., Vree, T., van Ewijk‐Beneken Kolmer, E., Koopmans, P., & van der Meer, J. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05721.x · Cited by 45
HIV Inhibitors: Problems and Reality
Tőzsér, J. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03909.x · Cited by 45
Izumi, T., Hoshiyama, K., Enomoto, S., Sasahara, K., & Sugiyama, Y. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36525-5 · Cited by 45
Levodopa – an exotoxin or a therapeutic drug?
Melamed, E., Offen, D., Shirvan, A., & Ziv, I. (2000) · Journal of Neurology · doi:10.1007/pl00022914 · Cited by 44
Amiodarone-cyclosporine interaction in a heart transplant patient.
Nicolau, D. P., Uber, W., Crumbley, A. J., & Strange, C. (1992) · PubMed · Cited by 44
Myeloperoxidase-mediated activation of xenobiotics by human leukocytes
Hofstra, A. H., & Uetrecht, J. (1993) · Toxicology · doi:10.1016/0300-483x(93)90066-2 · Cited by 44
Glutathione S‐transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis.
Green, V., Pirmohamed, M., Kitteringham, N. R., Knapp, M., & Park, B. K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04470.x · Cited by 44
Over-the-counter Analgesics: A Toxicologic Perspective
Jones, A. L. (2002) · American Journal of Therapeutics · doi:10.1097/00045391-200205000-00010 · Cited by 44
[Chronic active hepatitis and cirrhosis induced by wild germander. 3 cases].
Yahia, M. B., Mavier, P., Métreau, J., Zafrani, E., Fabrè, M., Gatineau-Sailliant, G., Dhumeaux, D., & Mallat, A. (1993) · PubMed · Cited by 43
Summan, M., & Cribb, A. E. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00060-1 · Cited by 43
N-Chlorination and oxidation of procainamide by myeloperoxidase: toxicological implications
Uetrecht, J., & ZAHID, N. D. (1991) · Chemical Research in Toxicology · doi:10.1021/tx00020a015 · Cited by 43
Cysteine-modifying agents: a possible approach for effective anticancer and antiviral drugs.
Casini, A., Scozzafava, A., & Supuran, C. T. (2002) · Environmental Health Perspectives · doi:10.1289/ehp.02110s5801 · Cited by 43
Koymans, L. M. H., van Lenthe, J. H., van de Straat, R., den Kelder, G. M. D.-O., & Vermeulen, N. P. E. (1989) · Chemical Research in Toxicology · doi:10.1021/tx00007a011 · Cited by 43
Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells
Sciulli, M. G., Seta, F., Tacconelli, S., Capone, M. L., Ricciotti, E., Pistritto, G., & Patrignani, P. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705078 · Cited by 43
The Role of Covalent Binding to Microsomal Proteins in the Hepatotoxicity of Acetaminophen
Holtzman, J. L. (1995) · Drug Metabolism Reviews · doi:10.3109/03602539509029827 · Cited by 42
Mechanism-Based Inactivation of Cytochrome P450 3A4 by L-754,394
Lightning, L. K., Jones, J. P., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., & Trager, W. F. (2000) · Biochemistry · doi:10.1021/bi992412u · Cited by 42
4‐Hydroxytamoxifen sulfation metabolism
Chen, G., Yin, S., Maiti, S., & Shao, X. (2002) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.10048 · Cited by 41
In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins
Sallustio, B. C., Knights, K., Roberts, B. J., et al. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90454-d · Cited by 41
Sedek, G., Jorga, K. M., Schmitt, M., Burns, R. S., & Leese, P. T. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199712000-00005 · Cited by 41
The effect of probenecid on paracetamol metabolism and pharmacokinetics
Kamali, F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315313 · Cited by 41
Phase II enzymes and bioactivation
Hinson, J., & Forkert, P. (1995) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y95-196 · Cited by 41
Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics*
Wong, S. L., Cavanaugh, J. H., Shi, H. H., Awni, W. M., & Granneman, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90166-6 · Cited by 41
Epe, B., Hegler, J., & Metzler, M. (1987) · Carcinogenesis · doi:10.1093/carcin/8.9.1271 · Cited by 40
DNA damage induced by catechol derivatives
Miura, T., Muraoka, S., Fujimoto, Y., & Zhao, K. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00156-3 · Cited by 40
Oral Contraceptives: An Update on Health Benefits and Risks
Borgelt, L. M. (2001) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)31329-8 · Cited by 40
Kassahun, K., & Abbott, F. S. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08205-4 · Cited by 40
Clinical and laboratory investigations in herbal poisonings
Deng, J. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00484-5 · Cited by 39
Species variation in the bioactivation of tacrine by hepatic microsomes
Madden, S. F., Spaldin, V., Hayes, R. N., et al. (1995) · Xenobiotica · doi:10.3109/00498259509061837 · Cited by 39
Hlavica, P. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120005646 · Cited by 39
Mulder, G. J., Kadlubar, F. F., Mays, J. B., et al. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15108-0 · Cited by 39
Mirtazapine versus selective serotonin reuptake inhibitors.
Thompson, C. (1999) · PubMed · Cited by 38
Park, K.-K., Chun, K., Yook, J. I., & Surh, Y. (1998) · PubMed · Cited by 38
Kitteringham, N. R., Kenna, J. G., & Park, B. K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04560.x · Cited by 38
Burrows, G. D., & Kremer, C. M. E. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199704001-00005 · Cited by 38
Triggle, D. J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00732-1 · Cited by 38
Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis
Eliasson, E., Gardner, I. B., Hume‐Smith, H., de Waziers, I., Beaune, P. H., & Kenna, J. G. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(98)00081-7 · Cited by 38
Human CYPs: in vivo and clinical aspects
Pelkonen, O. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001388 · Cited by 38
Ernst, E., & Pittler, M. H. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00077-4 · Cited by 38
Hapten Carrier Conjugates Associated with Halothane Hepatitis
Pohl, L. R., Thomassen, D. G., Pumford, N. R., Butler, L. E., Satoh, H., Ferrans, V. J., Perrone, A., Martin, B. M., & Martin, J. L. (1991) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5877-0_12 · Cited by 37
Wang, M., & DICKINSON, R. G. (1998) · PubMed · Cited by 37
Wells, P. G., & Vo, H. P. N. (1989) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(89)90244-5 · Cited by 37
Dihydralazine Hepatitis: Report of a Case and Review of the Literature
Pariente, A. E., Pessayre, D., Bernuau, J., Degott, C., & Benhamou, J. (2009) · Digestion · doi:10.1159/000198919 · Cited by 37
The mechanism of inhibition of cytochrome P450IIE1 by dihydrocapsaicin
Gannett, P. M., Iversen, P. L., & Lawson, T. A. (1990) · Bioorganic Chemistry · doi:10.1016/0045-2068(90)90041-3 · Cited by 37
Goebel, C., Vogel, C. F. A., Wulferink, M., Mittmann, S. G., Sachs, B., Schraa, S., Abel, J., Degen, G. H., Uetrecht, J., & Gleichmann, E. (1999) · Chemical Research in Toxicology · doi:10.1021/tx980001t · Cited by 37
CARDIOVASCULAR DRUG-DRUG INTERACTIONS
Anderson, J. R., & Nawarskas, J. J. (2001) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70209-5 · Cited by 36
Prostaglandin synthetase-catalyzed activation of phenacetin metabolites to genotoxic products.
Andersson, B. S., Nordenskjöld, M., Rahimtula, A. D., & Moldéus, P. (1982) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15142-0 · Cited by 36
Metabolic activation of the tricyclic antidepressant amineptine—I
Genève, J., Larrey, D. G., Lettéron, P., Descatoire, V., Tinel, M., Amouyal, G., & Pessayre, D. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90289-9 · Cited by 35
Mechanism-based inactivation of CYP2C11 by diclofenac.
Masubuchi, Y., Ose, A., & Horie, T. (2001) · PubMed · Cited by 35
N-Hydroxyacetaminophen: a postulated toxic metabolite of acetaminophen
Calder, I. C., Hart, S. J., Healey, K., & Ham, K. N. (1981) · Journal of Medicinal Chemistry · doi:10.1021/jm00140a014 · Cited by 34
Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease
Simonsen, U. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900846 · Cited by 34
Hospitalization for serious blood and skin disorders followinguse of co‐trimoxazole
Myers, M. W., & Jick, H. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00584.x · Cited by 34
Kitteringham, N. R., Lambert, C., Maggs, J. L., Colbert, J. E., & Park, B. K. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03358.x · Cited by 34
Drugs and the liver: advances in metabolism, toxicity, and therapeutics
Buratti, S., & Lavine, J. E. (2002) · Current Opinion in Pediatrics · doi:10.1097/00008480-200210000-00007 · Cited by 34
Vage, C., & Svensson, C. K. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07516-6 · Cited by 34
Tsarbopoulos, A., Gikas, E. E., Papadopoulos, N. T., Aligiannis, N., & Kafatos, A. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00905-4 · Cited by 33
Kassahun, K., & Baillie, T. A. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08087-0 · Cited by 33
Serino, F. M., Grevel, J., Napoli, K. L., Kahan, B. D., & Strobel, H. W. (1993) · Molecular and Cellular Biochemistry · doi:10.1007/bf01076094 · Cited by 32
Hoivik, D. J. (1996) · Fundamental and Applied Toxicology · doi:10.1006/faat.1996.0109 · Cited by 32
Zhou, L., Pihlstrom, B. L., Hardwick, J. P., Park, S. S., Wrighton, S. A., & Holtzman, J. L. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90135-6 · Cited by 32
Thalidomide, an antiangiogenic agent with clinical activity in cancer
Ng, S., Brown, M., & Figg, W. D. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(02)00177-4 · Cited by 32
Paracetamol-inhibitable COX-2.
Botting, R. (2000) · PubMed · Cited by 31
Nedelkov, D., & Nelson, R. W. (2001) · PROTEOMICS · doi:10.1002/1615-9861(200111)1:11<1364::aid-prot1364>3.0.co;2-h · Cited by 31
Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions
Reilly, T. P., & Ju, C. (2002) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200208000-00004 · Cited by 31
Fort, D. J., Stover, E. L., Bantle, J. A., & Finch, R. A. (2000) · Teratogenesis Carcinogenesis and Mutagenesis · doi:10.1002/(sici)1520-6866(2000)20:1<35::aid-tcm4>3.0.co;2-i · Cited by 31
Na, J. (1972) · PubMed · Cited by 30
Pharmacogenetics: more than skin deep
McLeod, H. L. (2001) · Nature Genetics · doi:10.1038/ng1101-247 · Cited by 30
Riley, R., Roberts, P., Coleman, M. D., Kitteringham, N. R., & Park, B. K. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03793.x · Cited by 29
Lai, W. G., Gardner, I. B., ZAHID, N. D., & Uetrecht, J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15359-7 · Cited by 29
The Effect of Probenecid on the Pharmacokinetics of Zalcitabine in HIV-Positive Patients
Massarella, J. W., Nazareno, L. A., Passe, S. M., & Min, B. H. (1996) · Pharmaceutical Research · doi:10.1023/a:1016009029536 · Cited by 27
Cellular toxicity of sulfamethoxazole reactive metabolites—I
Leeder, J. S., Dosch, H.-M., & Spielberg, S. P. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90629-j · Cited by 27
Chromatographic and electrophoretic methods for modified hemoglobins
Frantzen, F. (1997) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00245-4 · Cited by 27
Primary aromatic amines: their N-oxidative bioactivation
Hlavica, P., Golly, I., Lehnerer, M., & Schulze, J. (1997) · Human & Experimental Toxicology · doi:10.1177/096032719701600805 · Cited by 27
The mechanism of myeloperoxidase-catalysed oxidation of aminopyrine
Sayo, H., & Saitō, M. (1990) · Xenobiotica · doi:10.3109/00498259009046911 · Cited by 27
Genomics and the prediction of xenobiotic toxicity
Meyer, U.-A., & Gut, J. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00452-3 · Cited by 27
The effect of in vivo glutathione depletion with buthionine sulfoximine on rat embryo development
Hales, B. F., & Brown, H. M. (1991) · Teratology · doi:10.1002/tera.1420440305 · Cited by 27
Thalidomide in Solid Malignancies
Eisen, T. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.11.2607 · Cited by 27
Pons, C., Dansette, P. M., Amar, C., Jaouen, M., Wolf, C. R., Gregeois, J., Homberg, J., & Mansuy, D. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20545-6 · Cited by 27
Thalidomide in Multiple Myeloma
Kishi, Y., Oki, Y., & Machida, U. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421313 · Cited by 27
Isoform-Selective Metabolism of Mianserin by Cytochrome P-450 2D
Chow, T., Hiroi, T., Imaoka, S., Chiba, K., & Funae, Y. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15046-5 · Cited by 26
Mays, D. C., Pawluk, L. J., Apseloff, G., Davis, W. B., She, Z.-W., Sagone, A. L., & Gerber, N. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00151-o · Cited by 26
Raftery, M. J., & Geczy, C. L. (2002) · Journal of the American Society for Mass Spectrometry · doi:10.1016/s1044-0305(02)00359-8 · Cited by 26
Mifepristone: contraceptive and non-contraceptive uses
Ho, P. C., Ng, E. H. Y., & Tang, O. S. (2002) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200206000-00013 · Cited by 25
Shimizu, A., Nakanishi, T., Kishikawa, M., & Miyazaki, A. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00031-4 · Cited by 25
Liu, Z. C., McClelland, R. A., & Uetrecht, J. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06526-2 · Cited by 25
Karrow, N. A., McCay, J. A., Brown, R. D., Musgrove, D. L., Pettit, D. A. D., Munson, A. E., Germolec, D. R., & White, K. L. (2000) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2000.8939 · Cited by 24
Riley, R., Roberts, P., Kitteringham, N. R., et al. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90614-q · Cited by 24
Narimatsu, S., Arai, T., Watanabe, T., Masubuchi, Y., Horie, T., Suzuki, T., Ishikawa, T., Tsutsui, M., Kumagai, Y., & Cho, A. K. (1997) · Chemical Research in Toxicology · doi:10.1021/tx960165e · Cited by 24
Relationship between teratogeny and structure in the thalidomide field
Wuest, H. M., Fox, R. R., & Crary, D. D. (1968) · Cellular and Molecular Life Sciences · doi:10.1007/bf02138700 · Cited by 24
Cannell, G. R., Bailey, M. J., & DICKINSON, R. G. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02107-0 · Cited by 24
Newer Antidepressants: Hypotheses and Evidence
Shader, R. I., Fogelman, S. M., & Greenblatt, D. J. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199702000-00001 · Cited by 24
Divergent Effects of Raloxifene HCl on the the Pharmacokinetics and Pharmacodynamics of Warfarin
Miller, J. W., Skerjanec, A., Knadler, M. P., Ghosh, A., & Allerheiligen, S. R. B. (2001) · Pharmaceutical Research · doi:10.1023/a:1010904815275 · Cited by 22
Guan, X., Davis, M. R., Tang, C., Jochheim, C. M., Jin, L., & Baillie, T. A. (1999) · Chemical Research in Toxicology · doi:10.1021/tx990086d · Cited by 22
Koymans, L. M. H., den Kelder, G. M. D.-O., Koppele, J. M. T., & Vermeulen, N. P. E. (1993) · Xenobiotica · doi:10.3109/00498259309059401 · Cited by 22
Adverse Effects of Herbal Treatment of Cardiovascular Disease: What the Physician Must Know
Villegas, J. F., Barabe, D. N., Stein, R. A., & Lazar, E. J. (2001) · Heart Disease · doi:10.1097/00132580-200105000-00007 · Cited by 22
[Chronic cirrhogenic hepatitis induced by germander].
Dao, T., Peytier, A., Galateau-Sallé, F., & Valla, A. (1993) · PubMed · Cited by 22
Herbal Product Linked to Cancer
Greensfelder, L. (2000) · Science · doi:10.1126/science.288.5473.1946a · Cited by 21
Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation
Miller, J. L., & Trepanier, L. A. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0424-y · Cited by 21
Labbe, G., Descatoire, V., Beaune, P. H., Lettéron, P., Larrey, D. G., & Pessayre, D. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22744-6 · Cited by 20
Sadrieh, N. K., & Thomas, P. E. (1994) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1994.1156 · Cited by 20
Sousa, M. D., Pirmohamed, M., Kitteringham, N. R., Woolf, T. F., & Park, B. K. (1998) · Pharmacogenetics · doi:10.1097/00008571-199808000-00009 · Cited by 20
Update on clinical role of tamoxifen
Benson, J. R., & Pitsinis, V. (2003) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200302000-00003 · Cited by 20
Thalidomide in Cancer Treatment: A Potential Role in the Elderly?
Zhou, S., Kestell, P., Tingle, M. D., & Paxton, J. W. (2002) · Drugs & Aging · doi:10.2165/00002512-200219020-00002 · Cited by 18
Self-citationNjoku, D., Laster, M. J., Gong, D. H., Eger, E. I., Reed, G. F., & Martin, J. L. (1997) · Anesthesia & Analgesia · doi:10.1097/00000539-199701000-00031 · Cited by 18
Leeder, J. S., Lü, X., Timsit, Y., & Gaedigk, A. (1998) · Pharmacogenetics · doi:10.1097/00008571-199806000-00004 · Cited by 18
Abul‐Hajj, Y. J., & Cisek, P. L. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90212-9 · Cited by 18
Smith, B. R. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/003655101753352040 · Cited by 18
Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans
Vree, T. B., Kolmer, E. W. J. E.-B., Wuis, E. W., Hekster, Y. A., & Broekman, M. M. M. (1993) · Pharmacy World & Science · doi:10.1007/bf01880626 · Cited by 17
Comparative pharmacology of 'non-opioid' analgesics.
Brune, K. (1986) · PubMed · Cited by 17
Suzuki, K. T. (2001) · International Journal of Hematology · doi:10.1007/bf02981995 · Cited by 16
Mattei, A., Bizollon, T., Charles, J. D., Debat, P., Fontanges, T., Chevallier, M., & TREPO, C. G. (1992) · PubMed · Cited by 16
Metabolic activation of the antidepressant tianeptine
Lettéron, P., Descatoire, V., Tinel, M., Maurel, P., Labbe, G., Loeper, J., Larrey, D. G., Fréneaux, E., & Pessayre, D. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90620-5 · Cited by 14
Miyata, M., Tamura, E., Motoki, K., Nagata, K., & Yamazoe, Y. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.469 · Cited by 14
Severe trimethoprim induced neutropenia and thrombocytopenia.
Hawkins, T. D., Carter, J. M., Romeril, K., Jackson, S. R., & Green, G. J. (1993) · PubMed · Cited by 14
Hepatic covalent adduct formation with zomepirac in the CD26‐deficient mouse
WANG, M., Gorrell, M. D., Abbott, C. A., Jaggi, R., Marguet, D., & DICKINSON, R. G. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02662.x · Cited by 13
Lin, J. H., Chen, I., Chiba, M., Nishime, J. A., & Deluna, F. A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15064-7 · Cited by 13
Cytochrome P450 enzymes and UDP-Glucuronosyltransferases as hepatocellular autoantigens
Obermayer–Straub, P., & Manns, M. P. (1996) · Molecular Biology Reports · doi:10.1007/bf00351174 · Cited by 12
Clinical trial data on the cardioprotective effects of beta-blockade
Kendall, M. J. (2000) · Basic Research in Cardiology · doi:10.1007/s003950070005 · Cited by 11
Becquemont, L., Lecoeur, S., Simon, T., Beaune, P. H., Funck‐Brentano, C., & Jaillon, P. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00011 · Cited by 11
Characterization of the induction of rat microsomal cytochrome P450 by tacrine
Sinz, M., & Woolf, T. F. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00199-8 · Cited by 9
Immunochemical Detection of Drug-Protein Adducts in Acetaminophen Hepatotoxicity
Hinson, J., Roberts, D. W., Halmes, N. C., Gibson, J. D., & Pumford, N. R. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9480-9_7 · Cited by 8
Nohmi, T., Mizokami, K., KAWANO, S., et al. (1987) · PubMed · Cited by 7
Hutchins, G. M. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.7.733 · Cited by 5
[Licorice-induced high blood pressure].
Astrup, A. V. (2001) · PubMed · Cited by 3
Cited by
Bruderer, R., Bernhardt, O. M., Gandhi, T., Miladinović, S. M., Cheng, L.-Y., Messner, S., Ehrenberger, T., Zanotelli, V., Butscheid, Y., Escher, C., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044305 · Cited by 1,238
Tiwari, B., Sellamuthu, B., Ouarda, Y., Drogui, P., Tyagi, R. D., & Buelna, G. (2017) · Bioresource Technology · doi:10.1016/j.biortech.2016.11.042 · Cited by 817
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Metadata
- Authors
- Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 37
- Issue
- 1
- Pages
- 41-213
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W1997486990
- Cited by
- 274
- References
- 774
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.